reviewed april 2026|next review october 2026|88 physicians psi has verified|204 published studies
Semax
Semax is a synthetic heptapeptide derived from the ACTH(4-10) fragment, registered as a prescription medication in Russia for stroke recovery, cognitive disorders, and optic nerve disease, with over 200 published studies documenting BDNF upregulation and neuroprotective effects.
Evidence landscape: 204 published studies
204 published items. 10 human studies and 180 animal studies. Evidence base is deeper than most research peptides but concentrated in Russian-language literature.
- 10 Human
- 180 Animal
- 10 Reviews
- 4 Other research
Registered by the Russian Federation Ministry of Health for stroke recovery, cognitive disorders, and optic nerve disease. Used in Russian hospitals for decades.
Derived from the specific region of ACTH responsible for cognitive effects. Engineered to enhance brain function without affecting cortisol or the hormonal axis.
Over 200 published studies documenting consistent BDNF upregulation and neuroprotective effects. Evidence concentrated in Russian-language literature without Western replication.
PSI Assessment
Registered as a prescription medication by the Russian Federation Ministry of Health for stroke recovery, cognitive disorders, and optic nerve disease, Semax has been used in Russian hospitals for decades. It is a synthetic heptapeptide derived from the ACTH(4-10) fragment - the specific region responsible for cognitive effects - engineered to enhance brain function without affecting cortisol or the hormonal axis. Over 200 published studies document consistent BDNF upregulation and neuroprotective effects. The limitation shared with its companion compound Selank: virtually all clinical data originates from Russian institutions, and Western replication is absent.
Registered as a prescription medication in Russia for three indications. Over 200 published studies. BDNF upregulation without cortisol effects. No Western replication.
The mechanism centers on melanocortin receptor activation (MC3R, MC4R) in the brain without engaging MC2R on the adrenal cortex, which is why Semax enhances cognitive function without raising cortisol despite being derived from ACTH. The peptide robustly upregulates BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) through CREB-dependent transcription pathways. Intranasal delivery allows partial bypass of the blood-brain barrier.
What the evidence supports
Semax increases BDNF and NGF expression in brain tissue across multiple studies. It provides neuroprotection in ischemic models and is registered in Russia for stroke recovery, cognitive disorders, and optic nerve disease. The ACTH(4-10) mechanism enhances cognitive function without affecting cortisol. Clinical use in Russian hospitals spans decades. Over 200 published studies provide a substantial evidence base.
What is not yet established
Whether Semax's cognitive benefits extend to healthy adults without neurological conditions. Whether the Russian clinical data would replicate in Western-standard randomized controlled trials. Long-term safety with chronic nootropic use. Whether the N-acetyl variant (NA-Semax) offers clinically meaningful advantages.
Research Evidence
The findings below cover the Russian regulatory approval, the BDNF/NGF mechanism, and the Western replication limitation.
Evidence by condition
Evidence dimensions across Semax's investigated conditions. Stroke recovery and cognitive enhancement have the deepest human evidence, all from Russian institutions.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Stroke Recovery | ||||
| Cognitive Enhancement | ||||
| Optic Nerve Disease | ||||
| Neuroprotection |
Semax is registered in Russia for three clinical indications: stroke recovery, cognitive disorders, and optic nerve disease. Clinical use in Russian hospitals spans decades. This represents a level of regulatory validation and real-world clinical experience that most research peptides lack.
The Russian regulatory approval is meaningful but does not substitute for Western-standard randomized controlled trials. The approval data has not been independently reviewed by the FDA or EMA.
BDNF and NGF upregulation is one of the most consistently demonstrated mechanisms across both animal and human studies. BDNF (brain-derived neurotrophic factor) is the brain's primary growth and repair factor. Semax achieves this upregulation without affecting cortisol because it targets only the cognitive-active ACTH(4-10) fragment, not the adrenal MC2R receptor.
BDNF is a validated target in neuropsychiatry and neurodegeneration. The mechanism is pharmacologically sound. The question is whether the clinical benefits documented in Russian studies would replicate in Western trial designs.
Virtually all clinical evidence originates from Russian and Ukrainian research institutions. Zero Western clinical trials have been published. Over 200 published studies provide a substantial evidence base, but concentrated in Russian-language literature.
Without independent Western replication, the evidence cannot be fully evaluated to international standards. This is the primary confidence limiter for all Semax claims.
10 Human|180 Animal|10 Reviews
View all 204 indexed studiesHow Semax Works
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide analog of the ACTH(4-10) fragment that activates melanocortin receptors MC3R and MC4R in the brain without stimulating adrenal MC2R.
Semax increases BDNF, think of it as fertilizer for your brain cells. BDNF helps neurons grow, connect, and survive. By boosting it without triggering cortisol or other hormonal effects, Semax is designed to support brain function in a targeted way.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Semax activates melanocortin receptors (MC3R, MC4R) in the brain without stimulating MC2R on the adrenal cortex, explaining cognitive effects without cortisol elevation. It robustly upregulates BDNF and NGF through CREB-dependent transcription pathways. It modulates dopamine and serotonin turnover in the brain. In ischemic stroke models, Semax reduces infarct volume through BDNF-mediated neuroprotection, anti-inflammatory signaling, and improved microcirculation. The Pro-Gly-Pro C-terminal tail provides metabolic stability and has independent immunomodulatory activity.
What is Semax being studied for?
Researchers are studying Semax across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Semax overall. This means a compound can have human studies for one condition but only animal data for another.
Stroke Recovery
·Human TrialsSemax is registered in Russia for acute ischemic stroke. Clinical studies show improved neurological outcomes when administered within hours of stroke onset.
Limitations: All stroke data comes from Russian institutions. No Western-standard stroke randomized controlled trials exist.
Cognitive Enhancement
·Human TrialsAnimal and limited human studies show improvements in attention, memory, and learning. Semax increases BDNF and NGF in the hippocampus and prefrontal cortex.
Limitations: Whether cognitive benefits extend to healthy adults without neurological conditions is not established. No Western randomized controlled trials for cognitive endpoints.
Optic Nerve Disease
·Animal StudiesSemax is registered in Russia for optic nerve atrophy. Clinical data shows stabilization and improvement of visual function in some patients.
Limitations: Optic nerve data is limited to Russian clinical reports.
Neuroprotection
·Animal StudiesRobust animal data shows Semax protects neurons from ischemic, toxic, and oxidative damage through multiple mechanisms including BDNF upregulation and anti-inflammatory signaling.
Limitations: Translating neuroprotective findings from animal models to human clinical outcomes has historically been difficult across the field.
Safety and Regulatory Status
FDA Status: Not FDA-approved in the United States.
Russian Approval: Registered as a prescription medication in Russia for stroke recovery, cognitive disorders, and optic nerve disease.
Availability: Currently on the FDA Category 2 list, meaning licensed pharmacies cannot compound it. Expected to become available through licensed pharmacies following regulatory review per the February 2026 HHS announcement.
Semax has been used clinically in Russia for decades with a favorable safety profile. It does not affect cortisol despite being derived from ACTH. No significant adverse effects reported in clinical use. Administered intranasally.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Semax discussion.
Comparison and Related Research
Semax is most often compared with Selank (anxiolytic from same program), Thymosin Alpha-1 (Western-validated peptide), and Cerebrolysin (neuroprotective, different mechanism).
Head-to-head comparisons
Full research comparisons covering Semax and another peptide side by side.
Semax vs Selank
Research comparison of selank and semax, two Russian-developed neuropeptides for cognitive and anxiolytic research. Mechanisms, evidence levels, clinical backgrounds, and limitations analyzed.
View full comparisonSemax vs Cerebrolysin
Research comparison of Semax and Cerebrolysin, a synthetic ACTH-derived peptide versus a complex neuropeptide mixture. Mechanisms, evidence levels, administration contexts, and limitations analyzed.
View full comparisonSemax vs Cerebrolysin
Research comparison of Cerebrolysin and Semax, a complex porcine-derived neuropeptide mixture versus a synthetic ACTH-derived peptide. Mechanisms, evidence levels, administration contexts, and limitations analyzed.
View full comparisonSemax vs Dihexa
Dihexa has dramatic animal data but zero human evidence. Semax has Russian approval and decades of clinical use. Evidence-graded nootropic comparison.
View full comparisonRelated compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Foundational review by the research group that developed Semax, summarizing the rationale for designing a stabilized ACTH(4-10) analog with enhanced neuroprotective and nootropic properties. Covered preclinical and clinical experience across multiple neurological applications.Ashmarin IP et al., 2003 in Patol Fiziol Eksp Ter. View on PubMed
- 2.Clinical study evaluating Semax in patients with cerebrovascular insufficiency. Treatment reduced the rate of disease progression and exacerbation frequency, providing clinical evidence for neuroprotective effects in patients with compromised brain blood flow.Gusev EI et al., 2005 in Zh Nevrol Psikhiatr Im S S Korsakova. View on PubMed
- 3.Demonstrated that Semax increases brain-derived neurotrophic factor (BDNF) and its receptor trkB in the hippocampus, a brain region critical for memory and learning. BDNF supports the survival and growth of neurons, providing a molecular explanation for the cognitive-enhancing effects observed in earlier studies.Dolotov OV et al., 2006 in Brain Res. View on PubMed
- 4.Investigated the neuroprotective effects of Semax in an animal model of dopaminergic neuron damage. Treatment preserved dopamine system function and reduced behavioral deficits, suggesting potential relevance to neurodegenerative conditions affecting the dopamine pathway.Levitskaya NG et al., 2004 in Neurosci Behav Physiol. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.